Which has higher earnings & valuation, TTRX or PMVP?

Turn Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is TTRX or PMVP more profitable?

Turn Therapeutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A PMV Pharmaceuticals N/A -68.98% -62.70%

Do analysts recommend JMAC or PMVP?

PMV Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 206.51%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable valuation & earnings, JMAC or PMVP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is JMAC or PMVP more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A PMV Pharmaceuticals N/A -68.98% -62.70%

Do analysts prefer PMVP or SIGA?

PMV Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 206.51%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe PMV Pharmaceuticals is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, AVXL or PMVP?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is AVXL or PMVP more profitable?

Anavex Life Sciences' return on equity of -38.76% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -38.76% -35.01% PMV Pharmaceuticals N/A -68.98% -62.70%

PMV Pharmaceuticals (PMVP) Competitors

$1.30 +0.03 (+1.95%)

As of 11:58 AM Eastern

Compare

PMVP vs. TTRX, JMAC, CHRS, SIGA, and AVXL

Should you buy PMV Pharmaceuticals stock or one of its competitors? MarketBeat compares PMV Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PMV Pharmaceuticals include Turn Therapeutics (TTRX), Maxpro Capital Acquisition (JMAC), Coherus Oncology (CHRS), Siga Technologies (SIGA), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry.

How does PMV Pharmaceuticals compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Turn Therapeutics presently has a consensus target price of $8.00, suggesting a potential downside of 21.83%. PMV Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 206.51%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe PMV Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Turn Therapeutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

90.2% of PMV Pharmaceuticals shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Turn Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

In the previous week, Turn Therapeutics had 4 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 4 mentions for Turn Therapeutics and 0 mentions for PMV Pharmaceuticals. Turn Therapeutics' average media sentiment score of 0.00 equaled PMV Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Turn Therapeutics	Neutral
PMV Pharmaceuticals	Neutral

Summary

PMV Pharmaceuticals beats Turn Therapeutics on 6 of the 11 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Maxpro Capital Acquisition?

Maxpro Capital Acquisition (NASDAQ:JMAC) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Maxpro Capital Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

In the previous week, Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled PMV Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
PMV Pharmaceuticals	Neutral

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Maxpro Capital Acquisition's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

PMV Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 206.51%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Summary

PMV Pharmaceuticals beats Maxpro Capital Acquisition on 6 of the 9 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Coherus Oncology's average media sentiment score of 0.00 equaled PMV Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Coherus Oncology	Neutral
PMV Pharmaceuticals	Neutral

Coherus Oncology has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Coherus Oncology has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.25	$168.02M	$1.67	0.86
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Coherus Oncology currently has a consensus target price of $8.67, suggesting a potential upside of 503.95%. PMV Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 206.51%. Given Coherus Oncology's higher possible upside, analysts clearly believe Coherus Oncology is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Coherus Oncology has a net margin of 397.30% compared to PMV Pharmaceuticals' net margin of 0.00%. PMV Pharmaceuticals' return on equity of -68.98% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Summary

Coherus Oncology beats PMV Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Siga Technologies?

PMV Pharmaceuticals (NASDAQ:PMVP) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

In the previous week, PMV Pharmaceuticals' average media sentiment score of 0.00 equaled Siga Technologies'average media sentiment score.

Company	Overall Sentiment
PMV Pharmaceuticals	Neutral
Siga Technologies	Neutral

Siga Technologies has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Siga Technologies	$94.57M	2.65	$23.28M	$0.27	12.94

PMV Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 206.51%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe PMV Pharmaceuticals is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PMV Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Siga Technologies has a net margin of 21.58% compared to PMV Pharmaceuticals' net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Siga Technologies	21.58%	10.60%	8.94%

Summary

PMV Pharmaceuticals and Siga Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Anavex Life Sciences' return on equity of -38.76% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

In the previous week, Anavex Life Sciences had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 1 mentions for Anavex Life Sciences and 0 mentions for PMV Pharmaceuticals. Anavex Life Sciences' average media sentiment score of 1.34 beat PMV Pharmaceuticals' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anavex Life Sciences	Positive
PMV Pharmaceuticals	Neutral

Anavex Life Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Anavex Life Sciences presently has a consensus target price of $21.33, suggesting a potential upside of 748.24%. PMV Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 206.51%. Given Anavex Life Sciences' higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Anavex Life Sciences beats PMV Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get PMV Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMVP vs. The Competition

Export

Metric	PMV Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$69.60M	$3.07B	$6.80B	$12.40B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.88	20.40	27.08	24.12
Price / Sales	N/A	344.92	516.47	92.58
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.66	4.26	10.63	6.23
Net Income	-$77.74M	$65.94M	$3.60B	$331.53M
7 Day Performance	-8.10%	-1.55%	-1.08%	-1.30%
1 Month Performance	15.49%	0.11%	1.28%	-1.40%
1 Year Performance	-2.61%	16.96%	24.71%	18.15%

PMV Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMVP PMV Pharmaceuticals	2.3063 of 5 stars	$1.31 +2.0%	$4.00 +206.5%	-3.8%	$69.60M	N/A	N/A	50
TTRX Turn Therapeutics	0.6157 of 5 stars	$8.81 -4.1%	$8.00 -9.2%	N/A	$262.45M	N/A	N/A	2	Analyst Upgrade High Trading Volume
JMAC Maxpro Capital Acquisition	N/A	$19.11 +1.0%	N/A	+198.2%	$256.61M	N/A	N/A	2,021	Gap Up
CHRS Coherus Oncology	2.1968 of 5 stars	$1.63 -1.2%	$8.67 +431.7%	+61.2%	$251.43M	$42.17M	0.98	330
SIGA Siga Technologies	0.4151 of 5 stars	$3.50 -1.1%	N/A	-47.4%	$251.03M	$93.78M	12.96	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMVP) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. TTRX, JMAC, CHRS, SIGA, and AVXL

How does PMV Pharmaceuticals compare to Turn Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Maxpro Capital Acquisition?

Summary

How does PMV Pharmaceuticals compare to Coherus Oncology?

Summary

How does PMV Pharmaceuticals compare to Siga Technologies?

Summary

How does PMV Pharmaceuticals compare to Anavex Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. TTRX, JMAC, CHRS, SIGA, and AVXL

How does PMV Pharmaceuticals compare to Turn Therapeutics?

Do analysts recommend TTRX or PMVP?

Is TTRX or PMVP more profitable?

Do insiders & institutionals hold more shares of TTRX or PMVP?

Which has higher earnings & valuation, TTRX or PMVP?

Does the media refer more to TTRX or PMVP?

Summary

How does PMV Pharmaceuticals compare to Maxpro Capital Acquisition?

Which has more risk and volatility, JMAC or PMVP?

Does the media prefer JMAC or PMVP?

Do insiders and institutionals hold more shares of JMAC or PMVP?

Is JMAC or PMVP more profitable?

Do analysts recommend JMAC or PMVP?

Which has preferable valuation & earnings, JMAC or PMVP?

Summary

How does PMV Pharmaceuticals compare to Coherus Oncology?

Does the media refer more to CHRS or PMVP?

Which has more volatility and risk, CHRS or PMVP?

Do institutionals & insiders have more ownership in CHRS or PMVP?

Which has better earnings & valuation, CHRS or PMVP?

Do analysts recommend CHRS or PMVP?

Is CHRS or PMVP more profitable?

Summary

How does PMV Pharmaceuticals compare to Siga Technologies?

Does the media favor PMVP or SIGA?

Which has better earnings and valuation, PMVP or SIGA?

Do analysts prefer PMVP or SIGA?

Which has more risk and volatility, PMVP or SIGA?

Do institutionals & insiders have more ownership in PMVP or SIGA?

Is PMVP or SIGA more profitable?

Summary

How does PMV Pharmaceuticals compare to Anavex Life Sciences?

Which has preferable valuation & earnings, AVXL or PMVP?

Is AVXL or PMVP more profitable?

Does the media refer more to AVXL or PMVP?

Which has more volatility & risk, AVXL or PMVP?

Do analysts recommend AVXL or PMVP?

Do insiders & institutionals have more ownership in AVXL or PMVP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools